Upper Tract Urothelial Carcinoma

Predictors of Recurrence After RNU for Low-Grade UTUC

Publish Date May 15, 2022

Findings may inform surveillance strategies and improve treatment outcomes.

UTUC in Octogenarians Frequently Managed Without Surgery

Publish Date May 15, 2022

Approximately one-quarter of patients aged 80 years or older with upper tract urothelial carcinoma are managed expectantly, data show.

Time to Metastasis May Be a Surrogate for UTUC Survival After Surgery

Publish Date April 18, 2022

In a study, distant metastasis emerged as the best candidate to be a surrogate end point for survival among patients receiving surgical treatment for UTUC.

Segmental Ureterectomy Appears Non-Inferior to RNU in UTUC

Publish Date December 2, 2021

Segmental ureterectomy is increasingly adopted for high-risk upper tract urothelial carcinoma.

Current Smoking in UTUC Cases Predicts Post-RNU Disease Recurrence

Publish Date December 2, 2021

A recent study characterized disease recurrence patterns and predictive risk factors for recurrence in patients who underwent radical nephroureterectomy for low-grade upper tract urothelial carcinoma.

Kidney-Sparing Surgery Offers Effective Oncologic Control in High-Risk UTUC

Publish Date September 14, 2021

In this small study, even patients with high-risk tumors appeared to benefit from nephron-sparing surgery.

Older Adults May Benefit From NAC Prior to UTUC Radical Surgery

Publish Date September 13, 2021

Neoadjuvant chemotherapy prior to radical nephroureterectomy for upper tract urothelial carcinoma may improve pathologic outcomes regardless of age, new data suggest.

Epigenetic Test May Rule Out High-Grade UTUC

Publish Date September 12, 2021

If validated, the EpiCheck® assay may identify more patients who can safely delay or avoid nephroureterectomy.

Metastasectomy for Metastatic Urothelial Cancer Does Not Improve Survival

Publish Date August 3, 2021

A study showed that 2- and 5-year overall survival rates did not differ significantly between patients who underwent metastasectomy and those who did not.

Adjuvant Nivolumab Improves Outcomes in High-Risk Urothelial Carcinoma

Publish Date June 3, 2021

Nivolumab treatment for patients who have undergone radical surgery for high-risk muscle-invasive urothelial carcinoma improves their disease-free survival compared with placebo, a study shows.